Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline

Francesco Panza1, Vincenzo Solfrizzi, Anna M Colacicco

  • 1Department of Geriatrics, Center for Aging Brain, Memory Unit, University of Bari, Italy.

Insights

Lipid disorders in stroke patients are less studied than in heart disease. While statins show promise, more research is needed for effective stroke and dementia prevention strategies.

Area of Science:

  • Neurology
  • Cardiology
  • Gerontology

Background:

  • Lipoprotein disturbances in cerebrovascular disease (CVD) lack robust treatment data compared to coronary heart disease (CHD).
  • Statins have shown benefits in reducing cardiovascular events and also stroke-related events like brain infarction and transient ischemic attacks.
  • Vascular risk factors overlap between CVD, vascular dementia (VaD), and Alzheimer's disease (AD), suggesting interconnected pathways.

Purpose of the Study:

  • To investigate the relationship between vascular risk factors and the development and progression of Mild Cognitive Impairment (MCI) to dementia.
  • To estimate the prevalence, incidence, and progression rates of MCI to dementia in an elderly population.
  • To explore the influence of vascular risk factors on the progression of MCI to AD and VaD.

Main Methods:

  • Analysis of data from the Italian Longitudinal Study on Aging (ILSA).
  • Evaluation of 2963 individuals aged 65-84 with a 3.5-year follow-up period.
  • Correlation of vascular risk factors (e.g., serum total cholesterol, stroke history) with incident MCI and its progression to dementia.

Main Results:

  • A dementia progression rate of 3.8 per 100 person-years was observed.
  • Age was identified as a risk factor for incident MCI, while education showed a protective effect.
  • Serum total cholesterol had a non-significant borderline protective trend, and stroke showed a non-significant trend as a risk factor for MCI progression.

Conclusions:

  • In the studied population, 60% of MCI patients progressing to dementia developed AD, and 33% developed VaD.
  • Cerebrovascular disease and associated vascular risk factors may significantly influence the development of MCI and its progression to dementia.
  • Further research is warranted to clarify optimal lipid management strategies for stroke patients and to understand the role of vascular factors in cognitive decline.

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...